Emerging immunotherapy strategies in breast cancer Journal Article
| Authors: | Page, D. B.; Naidoo, J.; Mcarthur, H. L. |
| Article Title: | Emerging immunotherapy strategies in breast cancer |
| Abstract: | Although immunogenicity is typically associated with renal cell carcinomas and melanoma, there are several compelling reasons why immune-based therapies should be explored in breast cancer. First, breast cancers express multiple putative tumor-associated antigens, such as HER-2 and MUC-1, which have been the successful focus of vaccine development over the past decade, translating into tumor-specific immune responses and, in some cases, clinical benefit. Second, passive immune strategies with anti-HER-2 antibodies, such as trastuzumab and pertuzumab, have led to survival benefits in breast cancer. Finally, the successes observed with novel immunotherapeutic strategies, such as immune checkpoint blockade and adoptive T-cell therapies in other malignancies, combined with a growing body of literature that supports an interplay between solid tumors and the immune system, indicate that these strategies have the potential to revolutionize the treatment of breast cancer. © 2014 Future Medicine Ltd. |
| Keywords: | ipilimumab; breast cancer; immunotherapy; trastuzumab; tremelimumab; nivolumab; adoptive therapy |
| Journal Title: | Immunotherapy |
| Volume: | 6 |
| Issue: | 2 |
| ISSN: | 1750-743X |
| Publisher: | Future Medicine |
| Date Published: | 2014-02-01 |
| Start Page: | 195 |
| End Page: | 209 |
| Language: | English |
| DOI: | 10.2217/imt.13.166 |
| PROVIDER: | scopus |
| PUBMED: | 24491092 |
| DOI/URL: | |
| Notes: | Export Date: 3 March 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work